发病率和死亡率相关CAD仍然是对糖尿病患者的巨大挑战。糖尿病的血小板功能异常, 两个糖蛋白Ⅰb和Ⅱb / Ⅲa受体的表达增加, 使扩张血小板血管性假血友病因子和血小板纤维蛋白相互作用, 而导致糖尿病患者死亡和血栓性并发症的风险增加。多项研究表明:成功进行PCI后血管再建更需反复, 临床疗效差, DM仍然是一个极高的危险因素。虽然资料表明, 药物洗脱支架(DES)可减少阻塞率及重复再建血管与糖尿病状况无关, 但治疗的终点结果如心肌梗塞, 死亡率没有实质上的减少。然而, 也有许多其他随机试验比较多支的PCI使用DES或金属裸支架(BMS)跟冠状动脉搭桥术(CABG), 冠状动脉搭桥术优越性对糖尿病患者一直具有优越性。糖尿病患者和多支冠状动脉病变, 选择最优策略心肌血运重建是至关重要的。血运重建策略必须考虑到狭窄和移植物闭塞的风险较高, 以及病后遗症使糖尿病的介入治疗复杂化。当选择PCI时, 应倾向于使用DES和强有力的血小板抑制剂。当选择冠状动脉搭桥术时, 要考虑在围术期脑卒中的减少, 伤口感染的减少, 手术后的医疗管理的优化选择时, 要有利于糖尿病患者。患者的血糖控制有利于这两个策略。
Morbidity and mortality related to CAD remain a great challenge in patients with DM.Platelet function is abnormal in diabetes,expression of both glycoprotein Ib and Ⅱb/ Ⅲa is increased,augmenting both platelet-von Willebrand factor and platelet-fibrin interaction which leads to an increased risk of death and thrombotic complications in diabetics compared with nondiabetic patients.Multiple studies have shown that DM is a strong risk factor for restenosis following successful percutaneous coronary intervention (PCI) with greater need for repeat revascularization and inferior clinical outcomes though early data available suggest that drug eluting stents (DES) reduce restenosis rates and the need for repeat revascularization irrespective of the diabetic state and with no significant reduction in hard clinical endpoints such as myocardial infarction and mortality.However,there are so many other randomized trials comparing multivessel PCI using DES or bare metal stent (BMS) to coronary artery bypass grafting (CABG) which consistently demonstrated the superiority of CABG in patients with DM.Selection of the optimal myocardial revascularization strategy for patients with DM and multivessel coronary artery disease is crucial.Strategies for revascularization must take into account the higher risk for restenosis and graft occlusion,as well as the comorbid sequelae that complicate interventions in diabetic patients.When opting for PCI,the use of DES and potent platelet inhibitors should be favoured.And when opting for CABG,reduction in perioperative stroke,wound infection,and optimization of post-operative medical management will be of benefit to diabetic patients.Glycaemic control is beneficial to both strategies.
[1] Cook S,Windecker S.Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients[J].Best practice & research.Clinical endocrinology & metabolism,2009,23(3):317-334.
[2] Grech ED.ABC of Interventional Cardiology[M].london: BMJ Publishing Group Limited,2004 BMJ Books,1:1.
[3] Morel O,Kessler L,Ohlmann P,et al.Diabetes and the platelet:toward new therapeutic paradigms for diabetic atherothrombosis[J].Atherosclerosis,2010,212(2):367-376.
[4] Smith SC ,Jr.,Feldman TE,Hirshfeld JW Jr.,et al.ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)[J].Circulation,2006,113(1):156 - 175.
[5] Eagle KA,Guyton RA,Davidoff R,et al.TA.ACC/AHA 2004 guideline update for coronary artery bypass graft surgery:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)[J].Circulation,2004,110(14):e340-e437.
[6] Kumar P,Clark M.Kumar and Clark’s Clinical Medicine[M].7th Edition,2009,13:750-751.Elsevier Limited.
[7] John JM,Bhatt DL.Management of acute coronary syndrome in diabetes mellitus[J].Herz,2004,29(5):532-541.
[8] Machecourt J,Danchin N,Lablanche JM,et al.Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients:the EVASTENT Matched-Cohort Registry[J].Journal of the American College of Cardiology,2007,50(6):501-508.
[9] Banning AP,Westaby S,Morice MC,et al.Diabetic and non-diabetic patients with left main and/or 3-vessel coronary artery disease:comparison of outcomes with cardiac surgery and paclitaxel-eluting stents[J].Journal of the American College of Cardiology,2010,55(11):1067-1075.
[10] Daemen J,Kuck KH,Macaya C,et al.Multivessel coronary revascularization in patients with and without diabetes mellitus:3-year follow-up of the ARTS-Ⅱ (Arterial Revascularization Therapies Study-Part Ⅱ) trial[J].Journal of the American College of Cardiology,2008,52(24):1957-67.
[11] Kapur A,Hall RJ,Malik IS,et al.Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) Trial[J].Journal of the American College of Cardiology,2010,55(5):432 - 440.
[12] Ferreiro JL,Angiolillo DJ.Diabetes and antiplatelet therapy in acute coronary syndrome[J].Circulation,2011,123(7):798-813
[13] IIjima R,Ndrepepa G,Mehilli J,et al.Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era[J].American Heart Journal,2007,154(4):688-693.
[14] Lee SW,Park SW,Kim YH,et al.Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus:the DECLARE-DIABETES Trial[J].Journal of the American College of Cardiology,2008,51(12):1181-1187.
[15] Mohammad RA,Goldberg T,Dorsch MP,et al.Antiplatelet therapy after placement of a drug-eluting stent:a review of efficacy and safety studies[J].Clinical Therapeutics,2010,32(14):2265-2281.
[16] Shen XH,Jia SQ,Li HW.The influence of admission glucose on epicardial and microvascular flow after primary angioplasty.[J]Chinese Medical Journal,2006,119(2):95-102.
[17] Chi HJ,Zhang DP,Yang XC,et al.Hyperglycemia at admission and outcome in elderly patients with acute ST segment elevation myocardial infarction underwent primary percutaneous coronary intervention[J].Zhonghua Xin Xue Guan Bing Za Zhi,2009,37(7):595-598.
[18] Gasior M,Stasik-Pres G,Pres D,et al.Relationship between blood glucose on admission and prognosis in patients with acute myocardial infarction treated with percutaneous coronary intervention[J].Kardiologia Polska,2007,65(9):1031- 1040.
[19] Pres D,Gasior M,Strojek K,et al Blood glucose level on admission determines in-hospital and long-term mortality in patients with st-segment elevation myocardial infarction complicated by cardiogenic shock treated with percutaneous coronary intervention[J].Kardiologia Polska,2010,68(7):743-751.
[20] Chaitman BR ,Hardison RM,Adler D,et al.The Bypass Angiop;asty Revascularion Investigation 2 Diabetts randomized trial of diffetent treatment strategies in type 2 diabetes mellitus with stable ischemic heat disease:impact of treatment strategy on cadiac morality and myocardial infarction[J].Circulation,2009,120(25):2529-2540.
[21] Mehta SR,Yusuf S,Diaz R,et al Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction:the CREATE-ECLA randomized controlled trial[J].Journal of the American Medical Association,2005,293(4):437-446
[22] Wykrzykowska JJ,Raber L,de Vries T,et al.Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions:Results from the LEADERS multicentre trial substudy[J].Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,2009,5(3):310-317.
[23] Mahmud E,Bromberg-Marin G,Palakodeti V,et al.Clinical efficacy of drug-eluting stents in diabetic patients:A meta-analysis[J].Journal of the American College of Cardiology,2008,51(25):2385-2395.
[24] Patterson C,Mapera S,Li HH,et al.Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival:Role of AKT-dependent signaling[J].Arteriosclerosis,Thrombosis and Vascular Biology,2006,26(7):1473-1480.
[25] Grube E,Chevalier B,Smits P,et al.The SPIRIT V study:a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions[J].JACC Cardiovascular Interventions,2011,4(2):168-175.
[26] Kereiakes DJ,Cutlip DE,Applegate RJ,et al.Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents:Results from the SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system)[J].Journal of the American College of Cardiology,2010,56(25):2084-2089.
[27] Luscher TF,Creager MA,Beckman JA,et al.Diabetes and vascular disease:pathophysiology,clinical consequences,and medical therapy:Part Ⅱ[J].Circulation,2003,108(13):1655-1661.
[28] Stettler C,Wandel S,Allemann S,et al. Outcomes associated with drug-eluting and bare-metal stents:a collaborative network meta-analysis[J].Lancet,2007,370(9591):937 - 948.
